Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
Rhea-AI Summary
Prestige Consumer Healthcare (NYSE:PBH) closed its approximately $150 million cash acquisition of LaCorium Health on July 1, 2026, funded with cash and existing credit facilities.
Prestige also priced $400 million 6.25% senior notes due 2034 to redeem its $400 million 5.125% notes due 2028, and will report fiscal 2027 Q1 earnings on August 6, 2026 with a conference call at 8:30 a.m. ET.
LaCorium generates about $40 million revenue and is expected to deliver roughly $12 million EBITDA including anticipated synergies when fully integrated.
Positive
- Completed LaCorium Health acquisition for approximately $150 million in cash
- LaCorium generates about $40 million annual revenue and is expected to reach $12 million EBITDA with synergies
- Acquisition funded with cash on hand and existing credit facilities, implying no equity issuance
- Priced $400 million senior notes due 2034 to refinance existing $400 million notes
Negative
- New senior notes carry a 6.25% coupon versus 5.125% on notes being redeemed, implying higher interest expense
News Market Reaction – PBH
In the Jul 6 session, PBH declined 1.13%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | Debt offering | Neutral | -1.6% | Announced private offering of $400 million senior unsecured notes due 2034. |
| Jun 15 | Brand acquisition | Positive | -2.4% | Closed $1.045 billion Breathe Right brand acquisition expanding product portfolio. |
| Jun 05 | Conference participation | Neutral | +3.8% | Scheduled appearance at Oppenheimer Consumer Growth and E‑Commerce Conference. |
| May 13 | Earnings & acquisition | Negative | -11.3% | Reported fiscal 2026 results and announced LaCorium Health acquisition and guidance. |
| Apr 30 | Earnings date notice | Neutral | +0.5% | Set release and call date for fiscal 2026 Q4 and year‑end results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows notably negative reactions when Prestige pairs earnings or major acquisitions and financing actions, while routine announcements draw smaller, mixed moves.
Key Terms
senior notes financial
ebitda financial
rule 144a regulatory
regulation s regulatory
securities act regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of
Completion of LaCorium Health Acquisition
The Company completed the acquisition on July 1, 2026. The closing was finalized pursuant to the terms of the definitive agreement announced on May 13, 2026, under which Prestige agreed to acquire LaCorium for approximately
Founded in Australia and introduced in 1998, LaCorium is a leader in Australian therapeutic skin care designed to treat individual skin ailments. Products are sold under the Dermal Therapy®, Flexitol®, and Crampeze® brands in need-state categories such as lip care (cold sores), skin care (eczema & acne), foot care (heel balm, antifungal), hair & scalp (eczema), and more. Approximately
LaCorium generates approximately
Pricing of Senior Notes Offering
Prestige has also priced an offering of
The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes and related guarantees. Any offers of the notes and related guarantees will be made only by means of a private offering memorandum. The notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
First Quarter Fiscal 2027 Earnings Call
The Company will issue its fiscal 2027 first quarter earnings release on Thursday, August 6, 2026 before the market open. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “expected,” “will,” and “intends” (or the negative or other derivatives of each of these terms) or similar terminology. The “forward-looking statements” include, without limitation, statements regarding the Company’s expectations regarding the completion of the sale of the notes and the redemption of the 2028 notes. These statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including general economic and business conditions. A discussion of other factors that could cause results to vary is included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com
